List of Excipients in Branded Drug WAL ITIN

Generic Drugs Containing WAL ITIN

Company	Ingredient	NDC	Excipient
Walgreen Company	loratadine	0363-0699	LACTOSE MONOHYDRATE
Walgreen Company	loratadine	0363-0699	MAGNESIUM STEARATE
Walgreen Company	loratadine	0363-0699	POVIDONE

What are the Most Frequently-Used Excipients in WAL ITIN?

# Of NDCs	Excipient
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POVIDONE

WAL-ITIN Excipient Strategy and Commercial Opportunities for Loratadine

Last updated: August 27, 2026

WAL-ITIN is a Walgreens private-label loratadine product, generally marketed as a 10 mg oral antihistamine for seasonal allergic rhinitis and urticaria. Its commercial position depends on low manufacturing cost, reliable tablet performance, broad retailer distribution, and differentiation through dosage form, tolerability, packaging, and price rather than patent exclusivity. Loratadine is an established OTC active ingredient with no meaningful biosimilar risk and limited formulation IP barriers.[1][2]

What is WAL-ITIN and which active ingredient does it contain?

WAL-ITIN is associated with loratadine, a second-generation H1 antihistamine. The standard adult dose is 10 mg once daily. Loratadine is used for temporary relief of symptoms associated with hay fever, other respiratory allergies, and hives.[1]

Attribute	WAL-ITIN profile
Brand owner or retailer	Walgreens, through private-label sourcing
Active ingredient	Loratadine
Typical strength	10 mg
Product category	OTC antihistamine
Primary dosage form	Immediate-release oral tablet, with other loratadine formats available in the market
FDA pathway	OTC monograph or monograph-compliant labeling
Prescription requirement	No
Biosimilar exposure	None
Core competition	Claritin, store-brand loratadine, cetirizine, levocetirizine, fexofenadine
Patent dependence	Low
Commercial differentiator	Cost, availability, dosage form, packaging, and retailer placement

The precise inactive-ingredient profile can differ by WAL-ITIN stock-keeping unit, contract manufacturer, market, and dosage form. An excipient strategy should therefore distinguish the conventional 10 mg tablet from orally disintegrating, chewable, liquid, and combination products.

What excipients are appropriate for a WAL-ITIN loratadine tablet?

A conventional immediate-release loratadine tablet can use a standard direct-compression or wet-granulation platform. The target is a robust, low-cost tablet that meets disintegration, dissolution, content-uniformity, friability, and stability requirements.

Recommended excipient architecture

Formulation function	Candidate excipients	Commercial rationale
Diluent and compression base	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Controls tablet weight, hardness, and cost
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow and weight control
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Sweetener or flavor	Sucralose, aspartame, mannitol, flavor systems	Relevant to chewable and orally disintegrating products
Film coating	Hypromellose, polyethylene glycol, titanium dioxide or permitted colorants	Provides swallowability, branding, and moisture protection

For a low-cost standard tablet, microcrystalline cellulose combined with lactose or dibasic calcium phosphate provides a familiar manufacturing platform. Croscarmellose sodium or crospovidone can support fast disintegration without materially increasing cost.

Loratadine has limited aqueous solubility. The formulation should avoid unnecessary increases in tablet size and should target rapid disintegration and reproducible dissolution. Excipient selection alone will not create a major bioavailability advantage for a standard OTC tablet, but poor lubrication, excessive compression, or overcoating can delay dissolution and create quality risk.

Which excipient strategy offers the lowest-cost commercial product?

The lowest-cost strategy is usually a conventional immediate-release tablet using widely available compendial excipients and direct compression where powder flow permits.

Cost-optimized platform

A practical cost-focused design would use:

1. Microcrystalline cellulose or a lactose-cellulose co-processed base.
2. Crospovidone or croscarmellose sodium as the primary disintegrant.
3. Colloidal silicon dioxide for flow control.
4. Magnesium stearate at a controlled concentration.
5. A thin film coat only if required for appearance, taste, or handling.

Direct compression can reduce granulation time, water use, drying requirements, and process complexity. It also supports high-throughput production and fewer unit operations. Wet granulation remains useful if the active-excipient blend has poor flow, segregation, or content-uniformity performance.

The main cost risks are not the loratadine dose itself. They are packaging, contract manufacturing minimums, stability testing, retailer deductions, inventory requirements, and quality-control release costs. For a private-label OTC product, packaging and distribution can represent a larger commercial differentiator than marginal changes in tablet excipient cost.

What excipients support orally disintegrating and chewable WAL-ITIN products?

Orally disintegrating and chewable loratadine products offer the strongest formulation-led differentiation because the standard tablet market is highly commoditized.

Orally disintegrating tablet

An orally disintegrating tablet should prioritize:

• Mannitol for mouthfeel and low hygroscopicity.
• Crospovidone or low-substituted hydroxypropyl cellulose for rapid breakup.
• Crospovidone-based porous structures or specialized co-processed excipients.
• Sucralose or another high-intensity sweetener.
• Flavor systems that mask loratadine bitterness.
• Low-moisture packaging, such as aluminum-aluminum blister packs, when needed.

The formulation challenge is balancing rapid disintegration with mechanical strength. A weak tablet may break during blister filling or transport. A highly compressed tablet may fail the disintegration target. Moisture-sensitive taste-masked systems may require foil blisters rather than bottles.

Chewable tablet

A chewable formulation can use mannitol, sorbitol, xylitol, microcrystalline cellulose, starch, sweeteners, and flavor. It must avoid excessive grittiness, aftertaste, and tablet hardness. Sugar-free positioning may support consumers seeking reduced sugar intake, but polyol levels must be controlled because excessive consumption can produce gastrointestinal discomfort.

Chewable products can justify a higher retail price than standard tablets, but their economics depend on flavor development, tooling, stability, packaging, and consumer acceptance.

What formulation patents protect loratadine and WAL-ITIN?

Loratadine’s primary composition-of-matter protection has expired. Commercial loratadine products are not dependent on an active compound patent.

IP category	WAL-ITIN and loratadine exposure
Active ingredient patent	Expired
Standard tablet formulation patents	Generally expired, narrow, or commercially avoidable
Orally disintegrating formulation patents	Possible at the platform or product level, but not a general barrier to loratadine
Taste-masking patents	Potentially relevant to a new product, depending on formulation and jurisdiction
Packaging patents	Possible but generally narrow
Method-of-use patents	Limited relevance for ordinary allergy indications
Manufacturing process patents	Low barrier for standard loratadine tablets
Trademark rights	Relevant to WAL-ITIN and competing brand names

A new entrant should conduct a jurisdiction-specific freedom-to-operate review for any novel delivery system, taste-masking technology, multiparticulate platform, or combination product. A standard 10 mg loratadine tablet is unlikely to support meaningful blocking patent protection.

What is the FDA regulatory status of WAL-ITIN?

Loratadine is an OTC antihistamine active ingredient covered by FDA nonprescription-drug requirements and applicable monograph standards. Products must comply with active-ingredient conditions, labeling, dosage, warnings, packaging, quality, and manufacturing requirements.[1][3]

The product should carry a Drug Facts label addressing:

• Active ingredient and purpose.
• Uses.
• Warnings and contraindications.
• Directions by age group.
• Inactive ingredients.
• Storage information.
• Manufacturer or distributor details.

A conventional loratadine product does not require an abbreviated new drug application merely because it competes with Claritin. OTC monograph compliance, where applicable, provides the principal regulatory route. A materially novel dosage form, new active combination, or claim outside the monograph may require a different FDA pathway.

What is the Orange Book status of WAL-ITIN?

WAL-ITIN is generally a private-label OTC product, not an innovator prescription product relying on Orange Book-listed patents. The Orange Book is primarily relevant to approved prescription and certain related drug products, while OTC monograph products are regulated through a separate framework.[4]

This has several commercial implications:

• There is usually no Orange Book patent-listing strategy for the standard WAL-ITIN tablet.
• Paragraph IV litigation is not the normal entry mechanism for a monograph-compliant OTC loratadine product.
• Patent certification disputes are less central than FDA monograph compliance and trademark clearance.
• Retail substitution and private-label sourcing are more important than prescription-generic substitution rules.

When does loratadine lose exclusivity?

Loratadine lost meaningful market exclusivity years ago. Generic and store-brand versions have been widely available for many years, and the active ingredient is now a mature OTC commodity.

Exclusivity element	Status
New chemical entity exclusivity	Expired
Original composition patent	Expired
Prescription-to-OTC transition exclusivity	Expired
Standard formulation exclusivity	No broad active barrier
Current market access	Open to compliant OTC manufacturers

The commercial question is not when loratadine loses exclusivity. It is how efficiently a supplier can manufacture, package, register, distribute, and replenish the product.

Which companies compete with WAL-ITIN?

WAL-ITIN competes with both branded and private-label loratadine products.

Direct loratadine competitors

• Claritin, associated with Bayer and historically Schering-Plough.
• CVS Health store-brand loratadine.
• Amazon Basic Care loratadine.
• Walmart Equate loratadine.
• Generic products from Perrigo, Dr. Reddy’s, Teva, and other suppliers, depending on market and channel.

Therapeutic substitutes

• Cetirizine, marketed under Zyrtec and store brands.
• Levocetirizine, marketed under Xyzal and store brands.
• Fexofenadine, marketed under Allegra and store brands.
• Diphenhydramine and chlorpheniramine, which have older sedating-antihistamine profiles.

Loratadine’s principal positioning advantage is once-daily dosing with generally lower sedation than first-generation antihistamines. Its weakness is limited product differentiation in a market where consumers can switch among several nonprescription antihistamines.

What commercial opportunities exist for WAL-ITIN excipient innovation?

Pediatric dosage forms

Liquid and chewable products can target children and caregivers who have difficulty swallowing tablets. Opportunities include:

• Sugar-free liquids.
• Alcohol-free formulations.
• Unit-dose sachets or cups.
• Low-volume concentrated liquids.
• Improved flavor masking.
• Age-specific dosing devices.

The regulatory and safety burden is higher because dosing errors and age-based labeling require close control.

Senior-friendly products

Potential formats include easy-open but child-resistant packaging, smaller tablets, orally disintegrating tablets, and clear labeling. Excipient selection should avoid unnecessary allergens and reduce tablet size without compromising dissolution.

Allergen-conscious positioning

Lactose-free, gluten-free, dye-free, and low-sugar products can create marketing differentiation. These claims require supplier qualification, finished-product testing, and careful control of cross-contamination and label substantiation.

Combination products

Loratadine-pseudoephedrine combinations address congestion as well as allergy symptoms. They can generate higher retail value but face additional controls, supply-chain requirements, and regulatory complexity. Pseudoephedrine products also carry pharmacy-counter and purchase-tracking restrictions in the United States.

Premium delivery systems

Fast-dissolve, orally disintegrating, chewable, and liquid-filled formats may support higher gross margins. The strongest IP opportunity is likely to come from a genuinely differentiated delivery or taste-masking system, not from routine excipient substitution.

How strong is the patent estate for a new WAL-ITIN formulation?

The patent estate for a standard loratadine tablet is weak from a blocking perspective. A new formulation can still create a narrower, defensible estate around:

• Specific taste-masking matrices.
• Defined particle-size or solid-dispersion systems.
• Moisture-protective compositions.
• Orally disintegrating structures.
• Multiparticulate delivery.
• Pediatric liquid stability.
• Distinctive combination products.
• Manufacturing processes that materially improve yield or dissolution.

Patent strength will depend on unexpected performance, narrow claim drafting, reproducible manufacturing, and freedom from earlier loratadine formulation patents. A simple substitution of lactose for mannitol or crospovidone for croscarmellose is unlikely to produce durable exclusion.

What generic launch risks exist for WAL-ITIN?

The main launch risks are commercial and operational rather than patent-related.

Risk	Impact
Retailer concentration	Loss of Walgreens shelf space or private-label contract
Price competition	Rapid margin compression
Supply interruption	Stock-outs during allergy seasons
Packaging failure	Moisture exposure, label defects, or child-safety noncompliance
Flavor rejection	Particularly relevant to chewables and liquids
Dissolution variability	Potential batch failure or regulatory action
Inactive-ingredient claims	Risk from inaccurate allergen, sugar, or dietary claims
Seasonal demand	Working-capital and forecasting pressure
Contract-manufacturer dependence	Limited capacity flexibility

A generic or private-label entrant can launch without waiting for patent expiration, but commercial success requires retailer access and dependable supply. Seasonal allergy demand increases the value of manufacturing flexibility and inventory planning.

What licensing and partnering opportunities exist?

The most attractive licensing opportunities are in formulation technology rather than loratadine rights. Potential partners include:

• Taste-masking technology providers.
• Orally disintegrating tablet platform companies.
• Pediatric liquid and dosing-device developers.
• Contract development and manufacturing organizations.
• Private-label OTC distributors.
• Retail pharmacy chains seeking differentiated store brands.

A licensing deal should focus on measurable manufacturing or commercial advantages, such as reduced tablet weight, faster disintegration, improved flavor acceptance, longer stability, or lower packaging cost. A license covering only routine excipients is unlikely to justify substantial royalty economics.

Key Takeaways

• WAL-ITIN is a Walgreens private-label loratadine product with a mature OTC market position.
• Loratadine has no meaningful current composition-of-matter exclusivity barrier.
• The standard tablet should use a low-cost, compendial excipient system optimized for direct compression, disintegration, and dissolution.
• The strongest commercial opportunities are chewable, orally disintegrating, pediatric, sugar-free, dye-free, and combination products.
• Orange Book and Paragraph IV strategies have limited relevance to a conventional OTC monograph loratadine product.
• New IP is more credible around taste masking, delivery systems, stability, and manufacturing than around routine excipient selection.
• Retail access, supply reliability, packaging, and price are more important than patent exclusivity for commercial success.

FAQs

Can WAL-ITIN be reformulated as an orally disintegrating tablet?

Yes. Mannitol, crospovidone, flavoring, sweeteners, and moisture-protective packaging are suitable development components, subject to product-specific performance and regulatory testing.

Is lactose-free WAL-ITIN commercially viable?

Yes. A lactose-free tablet can use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or other suitable diluents. The product must support accurate inactive-ingredient labeling and consistent tablet performance.

Does loratadine require a biosimilar strategy?

No. Loratadine is a small-molecule chemical drug, not a biologic. Biosimilar provisions do not apply.

Can a new loratadine formulation receive patent protection?

Potentially, but routine excipient substitution is unlikely to provide strong protection. Patentability is more plausible for a specific delivery platform, taste-masking system, stability improvement, or manufacturing process with demonstrated technical advantages.

What is the best commercial dosage form for a new WAL-ITIN competitor?

The standard tablet offers the lowest manufacturing cost but limited differentiation. Chewable and orally disintegrating formats provide stronger commercial positioning, while pediatric liquids offer access to a distinct user segment with higher development and quality-control requirements.

References

1. U.S. Food and Drug Administration. (n.d.). Loratadine: OTC drug facts and antihistamine labeling requirements.
2. Walgreens. (n.d.). WAL-ITIN loratadine product information. Walgreens Boots Alliance.
3. U.S. Food and Drug Administration. (2022). Over-the-counter monograph drug products: Antihistamine drug products.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.